5 withdrawn. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Withdrawn 5 |
Follow Hypothalamic Neoplasms: new trials by email Literature Review of Hypothalamic Neoplasms trials Research Report on Hypothalamic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery Tranexamic acid, Placebo - Pituitary Tumor, Blood Loss | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2022-03-01 | 2022-04-05 | |
| Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers Lutetium Lu 177 Dotatate - Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-06-13 | 2020-09-07 | |
| Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas Farletuzumab - Resectable, Non-functioning Pituitary Adenoma | Phase 2 | Withdrawn | Morphotek | 2011-02-01 | 2013-11-04 | |
| Temozolomide in Treating Patients With Invasive Pituitary Tumors temozolomide, DNA methylation analysis, microarray analysis - Brain and Central Nervous System Tumors | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2009-12-01 | 2020-07-31 | |
| Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy antineoplaston A10, antineoplaston AS2-1, alternative product therapy - Merkel Cell Carcinoma, Islet Cell Carcinoma | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 |
Pituitary Neoplasms (5) · Growth Hormone-Secreting Pituitary Adenoma (2) · Adenoma, Acidophil (1) · Adenoma, Basophil (1) · Adenoma, Chromophobe (1) · Carcinoma, Islet Cell (1) · Carcinoma, Medullary (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Neuroendocrine (1) · Central Nervous System Neoplasms (1) · Hemorrhage (1) · Paraganglioma (1) · Parathyroid Neoplasms (1) · Pheochromocytoma (1) · Prolactinoma (1)
Brain Diseases (5) · Brain Neoplasms (5) · Central Nervous System Diseases (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Hypothalamic Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Nervous System Diseases (5) · Nervous System Neoplasms (5) · Pituitary Diseases (5) · Supratentorial Neoplasms (5) · Central Nervous System Neoplasms (4) · Neoplasms by Histologic Type (3)
Biological Therapy (1) · Complementary Therapies (1) · DNA Methylation (1) · Microarray Analysis (1) · Temozolomide (1) · Tranexamic Acid (1) · antineoplaston A10 (1) · antineoplaston AS 2-1 (1) · farletuzumab (1) · lutetium Lu 177 dotatate (1)
Burzynski Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Morphotek (1) · University of North Carolina, Chapel Hill (1)
United States (3)
Anthony Heaney, MD (1) · Brent Senior, MD (1) · Bruce Wallin, MD (1) · Camilo Jimenez (1) · Nelson Oyesiku, MD, PhD, FACS (1) · Stanislaw R. Burzynski, MD, PhD (1)